RU
EN

Bronchophage


Veterinary drug for prevention and treatment of diseases of the respiratory tract in animals
COMING SOON

Concentrated phage suspensions for inhalations

MICROMIR
Indications and usage
BRONCHOPHAGE
Bronchophage is a phage-based antibacterial preparation. Bacteriophages in the preparation provides a broad spectrum of bactericidal activity against common bacteria associated with diseases of the lower respiratory tract. Bronchophage is classified as a safe medication and does not cause tissue or mucous membranes irritation in recommended doses.
Bacteriophages in the preparation are highly specific and active against the actual strains of the following bacteria:
• Staphylococcus aureus
• Staphylococcus epidermidis
• Providencia rettgeri
• Enterobacter kobei
• Citrobacter freundii
• Bacteroides fragilis
• Propionibacterium acnes
• Streptococcus pyogenes
• Streptococcus haemolyticus
• Salmonella enteritidis
• Salmonella typhimurium
• Salmonella infantis
• Wolinella spp.
• Treponema denticola
• Aggregatibacter actinomycetemcomitans
• Pseudomonas aeruginosa
• Acinetobacter baumannii
• Escherichia coli
• Klebsiella pneumoniae
• Proteus vulgaris
• Proteus mirabilis
• Moraxella cataralis
• Enterococcus faecalis
01
Dosage form
The preparation is produced in 10 ml glass vials containing 2 ml of clear, light-yellow liquid of sterile concentrate of phage lysates.
02
Composition
Phage particle suspension effective against pathogenic and opportunistic pathogenic bacteria causing diseases of upper and lower respiratory tract.
03
Storage conditions
Store the preparations in a closed manufacturer's original packaging, in a dry place away from direct sunlight, separately from non-medications, at temperatures of 2-8 °C. The transportation is allowed at temperature between 0 °C and 25 °C (no direct sunlight) for up to 30 days. Shelf life under storage conditions: for products in liquid form is 1 year from the date of manufacture. The phage lysate solution diluted in normal saline under aseptic conditions can be stored for up to one year at 2-8 °C. Do not use the phage lysate concentrate or phage lysate solution if there is lack of clarity.
Dispose of unused preparations in accordance with the legal requirements.
04
Indications and usage
Bronchophage is used for prevention and treatment of diseases of lower respiratory tract, including in combination therapy of chronic obstructive bronchitis and chronic obstructive pulmonary disease in horses.
Dilutions: 2 ml of Bronchophage concentrate should be diluted in 60 ml of sterile normal saline. Do not use if the solution is clouded, contains flakes or has precipitated.
For inhalation, ultrasonic nebulizers are used, e.g. Air-One inhaler, Germany.

DOSAGE:
The diluted preparation volume should be sufficient for the 20-25 minutes inhalation. Depending on the individual horse's breathing rate, the consumption of the solution is 40-50 ml per one procedure.
The inhalation is applied 4 times at intervals of 5-7 days. In some complicated cases, one additional inhalation is required.
It is recommended to start inhalation in 1-1.5 hours after feeding or exercising.
Do not feed or water horses for 1 hour after the inhalation.
After a course of inhalation with the bacteriophage preparation, it is recommended to use saline solution in inhalations with Air-One ultrasonic inhaler for 7-10 days.

PERSONAL PREVENTIVE MEASURES:
No special precautions are required when using Bronchophage. After work, hands should be thoroughly washed with warm running water and soap. It is not allowed to smoke, eat or drink while working with the preparation.
Do not use empty syringes dispensers for household purposes. Dispose of them with household waste.
05
Contraindications
Individual hypersensitivity of the animal to Bronchophage components.
No side effects or complications after the preparation administration have been observed.


Please read the instructions before use.

Any questions?
Contact Us

Phone: +7 (495) 625-32-65
Mail: office@micromir.bio